Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
Are TKIs safe for a patient with metastatic renal cell carcinoma and a transplanted kidney?
No contraindications from my experience, and does not look like there are any known interactions or interactions with metabolism. It is helpful to make sure the treating nephrologist is aware of the diagnosis and therapy in order to monitor immunosuppression levels. Often we will change the immunosu...
What is your approach to the treatment of gamma heavy chain disease (Franklin's disease)?
This is such a rare entity and it has been treated with so many different regimens.It is hard to diagnose and I have seen very a handful of cases over the years. The presentation can be variable and include lymphadenopathy, anemia, splenomegaly, skin involvement, thrombocytopenia, and rarely hepatom...
How would you approach moderate neutropenia (ANC < 1000) in a solid organ transplant recipient?
There are limited data addressing the safety and efficacy of G-CSF in the solid-organ post-transplantation setting. Most case series report no increase in graft rejection with G-CSF treatment, although this question is not rigorously answered. Most cases of neutropenia in the post solid-organ transp...
Do you incorporate immunotherapy in your multi-modality treatment after chemoradiation for patients with potentially resectable stage III superior sulcus NSCLC?
No. Durvalumab therapy in NSCLC is currently limited to patients with unresectable disease. PACIFIC clearly demonstrated an enduring survival benefit of consolidative Durvalumab therapy after combined chemo-radiation therapy in patients who did not undergo surgical resection. The NeoCOAST trial is c...
For patients with metastatic thymic carcinoma, what would you offer patients who progress after platinum doublet chemotherapy?
Thymic carcinoma is a rare tumor and carries a much different prognosis than thymoma, which is often more indolent and for which surgery is the mainstay of treatment. Unfortunately, thymic carcinomas tend to respond poorly to chemotherapy. For an unresectable thymic carcinoma, radiation is typically...
What is your approach to gynecologic examinations/surveillance in a standard risk patient on adjuvant tamoxifen?
In the absence of symptoms (abnormal bleeding or discharge, pain, etc.), I do not recommend gynecologic examinations/surveillance beyond what is appropriate given the woman's age. First, premenopausal women on tamoxifen are not at increased risk of developing endometrial cancer. In postmenopausal wo...
How would you approach a patient with BRAF V600E mutated dMMR stage II colon cancer?
One could consider checking circulating tumor DNA. This is an evolving technology in colon cancer that might sway you to offering adjuvant chemotherapy if this test suggested a high risk of recurrence.
What is you approach for first line treatment in an elderly patient >85 years of age with good PS and a hairy cell leukemia variant?
The 1st question is: does he need treatment? Such as significant cytopenia(s), symptomatic splenomegaly, or constitutional symptoms? If so, and at > 85 yo, I will probably try rituximab alone after discussing with him that this is typically reserved for a relapsed disease, but the alternative is che...
Would you include carboplatin with an anthracycline and taxane for neoadjuvant treatment for triple negative inflammatory breast cancer?
It's important to talk about such an option that exists if the patient is young and does not have major comorbidities. But, adding the carboplatin for the TN-IBC is not absolutely required. The IBC experts have had multiple discussions about this issue.There are some data in the non-IBC setting abou...
Would you use a myeloablative or reduced intensity conditioning regiment for a pediatric or AYA patient who does not recover their counts after treatment for AML, but remains disease free?
I would use a myeloablative regimen, if medically fit and eligible. In fact, I would worry that there is a residual disease (that you're unable to detect) behind the lack of CBC recovery which is another reason to use a myeloablative regimen.